GGrantIndex
← Leaderboards

Zheng David Qian

Oregon Health & Science University

$4,913,102
Attributed
$4,913,102
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $768.8K · FY201025
$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,913,102 · 4

By mechanism

R01$4,913,102 · 4

Top collaborators

No co-investigators on record.

Most similar at Oregon Health & Science University

Same institution · by research overlap

Others in their field

Top investigators on “In Vitro

Research focus

In VitroIn VivoXenograft ProcedureGrowthMediatingCancer PatientMalignant NeoplasmsHypoxia Inducible Factor 1Animal ModelProteinsClinical TrialsMetabolismMetabolicMolecularImmunohistochemistryOncogenicTumorBiologicalGlutaminePathway InteractionsResistanceMolecular TargetProtein DegradationOverexpression

Grant awards (16)

Developing therapies to improve enzalutamide in CRPC$416,508
R01 · FY2025 · CA · contact PI
Adaptive resistance to AR inhibitors in hypoxia by GPT1$123,201
R01 · FY2025 · CA · contact PI
Developing therapies to improve enzalutamide in CRPC$395,685
R01 · FY2024 · CA · contact PI
Adaptive resistance to AR inhibitors in hypoxia by GPT1$334,662
R01 · FY2024 · CA · contact PI
Developing therapies to improve enzalutamide in CRPC$416,508
R01 · FY2023 · CA · contact PI
Adaptive resistance to AR inhibitors in hypoxia by GPT1$352,275
R01 · FY2023 · CA · contact PI
Adaptive resistance to HIF1a inhibition in hypoxia$352,232
R01 · FY2020 · CA · contact PI
Adaptive resistance to HIF1a inhibition in hypoxia$341,648
R01 · FY2019 · CA · contact PI
Adaptive resistance to HIF1a inhibition in hypoxia$352,269
R01 · FY2018 · CA · contact PI
Adaptive resistance to HIF1a inhibition in hypoxia$352,147
R01 · FY2017 · CA · contact PI
Adaptive resistance to HIF1a inhibition in hypoxia$352,242
R01 · FY2016 · CA · contact PI
HIF1a N-terminus hyperacetylation and anticancer mechanism of hydroxamic-HDACi$220,610
R01 · FY2014 · CA · contact PI
HIF1a N-terminus hyperacetylation and anticancer mechanism of hydroxamic-HDACi$213,786
R01 · FY2013 · CA · contact PI
HIF1a N-terminus hyperacetylation and anticancer mechanism of hydroxamic-HDACi$227,432
R01 · FY2012 · CA · contact PI
HIF1a N-terminus hyperacetylation and anticancer mechanism of hydroxamic-HDACi$227,432
R01 · FY2011 · CA · contact PI
HIF1a N-terminus hyperacetylation and anticancer mechanism of hydroxamic-HDACi$234,465
R01 · FY2010 · CA · contact PI